Roche has received a CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test is expected to be made available to countries that accept the CE mark products standards by mid-February 2021. The new test allows patients to self-collect samples from their nose, a simpler and quicker procedure than its previous test.

Australia-based medical technology manufacturer Ellume has struck a deal with the US Biden administration to scale up the production of its rapid Covid-19 home tests. The deal was worth $230m and will see the making and distribution of the home tests in the US. The deal also includes the purchase of 8.5 million Covid-19 tests that will be distributed across the country.

Diagnostic maker Cellex has collaborated with HealthDatix and Spartan Medical to make available its qSARS-CoV-2 Antigen Rapid Test to local, state, and federal governments. The test can be used to detect and address the B.1.1.7 and other variant strains found in the UK, US, Brazil, and South Africa.